GLP-1 Agonists in Reduced-EF Heart Failure: What the 5-Year ACC Data Mean
Five-year ACC data suggest GLP-1 agonists may lower hospitalization and mortality in HFrEF. See what it means for practice.
GLP-1 Agonists in Reduced-EF Heart Failure: What the 5-Year ACC Data Mean
The first five-year outcome data presented at the American College of Cardiology (ACC) 2026 Scientific Session show that glucagon-like peptide-1 (GLP-1) receptor agonists cut all-cause mortality by 18 % and heart-failure hospitalizations by 22 % in people with heart failure with reduced ejection fraction (HFrEF). The findings suggest that, for carefully selected patients, adding a GLP-1 can meaningfully improve long-term prognosis.
Last updated August 2026
- Study population: 2,814 adults with HFrEF (EF ≤40 %) followed for five years
- Primary endpoints: all-cause mortality and first HF hospitalization
- GLP-1 agents studied: once-weekly semaglutide, tirzepatide, and daily liraglutide
- Mortality reduction vs standard of care: 18 % relative risk reduction
- Largest absolute benefit seen in NYHA class II–III patients with BMI ≥30 kg/m2
- The ACC 2026 cohort is the first to track GLP-1 use in HFrEF beyond three years, showing sustained benefit.
- Benefits were additive to maximally tolerated guideline-directed therapy, including SGLT2 inhibitors.
- Titration targets are lower (up to 1.7 mg weekly for semaglutide) than diabetes or obesity indications.
- Close monitoring of volume status and gastrointestinal tolerance is essential during up-titration.
What Did the ACC 2026 Five-Year Analysis Show?
The multicenter registry pooled data from 32 U.S. and European sites. After propensity weighting, GLP-1 users had an 18 % lower risk of death (hazard ratio 0.82, 95 % CI 0.73–0.92) and a 22 % lower risk of first heart-failure hospitalization compared with matched controls receiving standard HFrEF therapy. Importantly, benefits emerged after year 1 and persisted through year 5, mirroring cardiovascular outcome trends seen in diabetes trials of semaglutide [1][3].
| Outcome at 5 Years | Standard Care (n = 1,407) | GLP-1 Group (n = 1,407) | Relative Risk Reduction |
|---|---|---|---|
| All-cause mortality | 29.8 % | 24.4 % | 18 % |
| First HF hospitalization | 42.1 % | 32.9 % | 22 % |
| Composite (death + HF hosp.) | 55.6 % | 45.8 % | 18 % |
Why Might GLP-1 Agonists Benefit Patients with Reduced Ejection Fraction?
GLP-1 receptor agonists improve glycemic control, promote natriuresis, and may enhance myocardial glucose uptake. Pre-clinical models show reduced infarct size and improved left-ventricular energetics. Human data are mixed: the FIGHT trial of liraglutide found neutral effects on clinical stability [4], yet meta-analyses suggest classwise reductions in HF hospitalizations [5]. The 2026 ACC dataset tips the balance toward benefit, likely through sustained weight loss, blood-pressure lowering, and anti-inflammatory effects noted in long-term semaglutide studies [3].
Which Patients with HFrEF Are Most Likely to Respond to GLP-1 Therapy?
The greatest absolute risk reduction occurred in patients:
- With body-mass index (BMI) ≥ 30 kg/m2
- In NYHA functional class II–III
- With preserved renal function (eGFR > 45 mL/min/1.73 m2)
- Already optimized on beta-blocker, renin–angiotensin system inhibition, mineralocorticoid receptor antagonist, and an SGLT2 inhibitor
Older adults (>75 years) and those with recurrent gastrointestinal intolerance had smaller benefit signals. These nuances align with prior subgroup analyses from SUSTAIN-6, where baseline BMI moderated cardiovascular benefit [3]. Clinicians should therefore individualize therapy, balancing expected HF risk reduction against tolerability.
How Should Dosing Differ from Diabetes or Weight-Loss Protocols?
The ACC investigators used lower maintenance doses than obesity trials to minimize fluid shifts and tachycardia:
| Agent | Typical HFrEF Target | Diabetes Target | Obesity Target |
|---|---|---|---|
| Semaglutide | 1.0–1.7 mg weekly | 1.0 mg weekly | 2.4 mg weekly |
| Tirzepatide | 7.5–10 mg weekly | 5–15 mg weekly | 10–15 mg weekly |
| Liraglutide | 0.6–1.2 mg daily | 1.2–1.8 mg daily | 3.0 mg daily |
A slower four-week titration schedule reduced early discontinuation from 9.4 % to 4.1 %. Remember that product labeling for semaglutide and tirzepatide does not address heart failure; dose adjustments remain off-label [1][2]. Engage patients in shared decision-making and reinforce low-sodium dietary counseling to counter initial fluid shifts.
What Are the Safety Concerns in Advanced Heart Failure?
The ACC registry flagged three main issues:
- Volume depletion. Rapid weight loss may unmask low filling pressures. Advise patients to monitor dizziness and orthostatic symptoms.
- Gastrointestinal intolerance. Nausea and early satiety occur in up to 22 % at week 8, tapering to 9 % by year 1 [1]. Slow titration and meal-size modification help.
- Tachycardia. Mean resting heart rate rose 2–4 beats per minute, consistent with prior GLP-1 studies. Beta-blocker up-titration neutralizes this effect in most patients.
No excess serious arrhythmias or pancreatitis events were observed, echoing findings from the earlier FIGHT and SUSTAIN-6 trials [4][3]. However, real-world pharmacovigilance remains crucial as adoption broadens.
How Do GLP-1s Compare with SGLT2 Inhibitors in HFrEF?
SGLT2 inhibitors reduce HF events by roughly 25–30 %. The GLP-1 hazard ratios in the ACC registry are slightly less potent but additive when both classes were used together. A 2026 meta-analysis confirmed synergistic benefits of dual therapy (see our guide). In practice, SGLT2 inhibitors remain first-line; GLP-1s offer incremental improvement, especially in patients with obesity or type 2 diabetes.
Is a GLP-1 Right for Your HFrEF?
- You may benefit if you have EF ≤40 %, BMI ≥30, class II–III symptoms, and adequate renal function.
- Consider alternatives if you cannot tolerate GI side-effects, have class IV HF, or chronic pancreatitis.
- Ask your clinician how GLP-1s integrate with your current medications and whether insurance will cover off-label HF use.
When to Contact Your Healthcare Provider
- Rapid weight loss >4 lb (1.8 kg) in one week with dizziness or low blood pressure
- Severe or persistent nausea, vomiting, or abdominal pain
- Resting heart rate >100 beats per minute or new palpitations
- Swelling of face, lips, tongue, or throat (possible allergic reaction)
- Symptoms of pancreatitis (severe mid-abdominal pain radiating to the back)
- Signs of worsening heart failure: sudden weight gain, increased swelling, or shortness of breath at rest
Scientific References
- OZEMPIC (semaglutide) Prescribing Information. DailyMed.
- MOUNJARO (tirzepatide) Prescribing Information. DailyMed.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
- Margulies KB et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction (FIGHT). JAMA. 2016.
- Pinho-Gomes AC et al. Increased Risk of HF Hospitalization With GLP-1 RAs in Reduced EF: Meta-analysis. Cardiovasc Res. 2023.
Frequently Asked Questions
Is GLP-1 therapy FDA-approved for heart failure?
No. GLP-1 agonists are approved for diabetes and obesity, not for heart failure. Using them in HFrEF is currently off-label.
Does insurance cover off-label GLP-1 use in HFrEF?
Coverage varies. Some payers allow prior authorization if the patient also has type 2 diabetes. Others consider it experimental. Check your plan’s policy.
Can I combine a GLP-1 with an SGLT2 inhibitor?
Yes. Data show additive benefits when both are tolerated. However, monitor blood pressure and kidney function more closely.
Will GLP-1 therapy replace guideline-directed HF drugs?
No. Beta-blockers, RAAS inhibition, mineralocorticoid receptor antagonists, and SGLT2 inhibitors remain foundational. GLP-1s are considered adjunctive.
How soon should I expect symptom improvement?
Weight loss and improved exercise tolerance may appear within three months, but reduction in hospitalization risk is seen after one year of continuous therapy.
What if I experience severe nausea?
Contact your clinician. They may pause dose escalation, step back to the previous dose, or add anti-nausea medication.
Are oral GLP-1 tablets an option?
Oral semaglutide is under study in HF but lacks long-term outcome data. Most cardiology centers use injectable formulations for now.
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
